SMN1 and proximal spinal muscular atrophy: Recently, a gene replacement therapy named Zolgensma (onasemnogene abeparvovec-xioi, AVXS-101) was approved by the FDA for paediatric SMA patients with bi-allelic mutations in the SMN1 gene [89].